With a market capitalization (market cap) of $1.36B — a measure of how much the company is worth — Tyra Biosciences, Inc. ranks #2,220 among the 2,416 companies tracked, and 309th in Healthcare as of November 17, 2026. Shares trade at $19.67, down 0.44% on the day.
As of November 17, 2026 · Prices may be delayed
of 2,416 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 16, 2026. The headline market cap is from the ranking update on November 17, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 16, 2026 | $1.38B | -15.22% | $19.74 |
| 2025 | Dec 31, 2025 | $1.62B | +96.82% | $26.29 |
| 2024 | Dec 31, 2024 | $824.78M | +38.60% | $13.90 |
| 2023 | Dec 29, 2023 | $595.08M | +85.51% | $13.85 |
Ranking figure $1.36B as of November 17, 2026.
Market cap = share price × shares outstanding.
Tyra Biosciences, Inc.'s ranking market cap is the reported market cap from the latest ranking update, with a share price of $19.45 as of November 17, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.38B on November 16, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 59,602,328 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.16B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $19.45. The headline price of $19.67 is from the ranking update on Nov 17, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.33T | -1.18% |
| #20 | Johnson & Johnson JNJ | $673.59B | -0.98% |
| #23 |
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 17, 2026, Tyra Biosciences, Inc. (TYRA) is worth $1.36B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Tyra Biosciences, Inc.’s book equity is about $259.18M. Market cap is the market value of the outstanding shares. As of November 17, 2026, its market cap is $1.36B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Tyra Biosciences, Inc. ranks #2,220 among the 2,416 companies tracked on MarketCapLens. In Healthcare it ranks #309 of 350.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 | Dec 30, 2022 | $320.78M | -45.13% | $7.60 |
|---|
| 2021 | Dec 31, 2021 | $584.63M | — | $14.07 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Undefined when revenue is zero
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $517.75B |
| -0.60% |
| #30 | UnitedHealth Group Incorporated UNH | $354.98B | -3.92% |
| #31 | Merck & Co., Inc. MRK | $354.79B | -0.39% |
| #37 | Novartis AG NVS | $301.28B | -0.42% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2217 | GeneDx Holdings Corp. WGS | $1.36B | -12.89% |
| #2218 | ATRenew Inc. RERE | $1.36B | +1.24% |
| #2219 | Universal Insurance Holdings, Inc. UVE | $1.36B | +0.21% |
| #2221 | Peoples Bancorp Inc. PEBO | $1.36B | -1.29% |
| #2222 | Himax Technologies, Inc. HIMX | $1.36B | -2.39% |
| #2223 | Preformed Line Products Company PLPC | $1.35B | +0.22% |
Tyra Biosciences, Inc.’s ranking market cap of $1.36B comes from the same snapshot as the rest of this site, as of November 17, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 59,602,328. The historical market-cap series last observed $1.38B on November 16, 2026.
Over the past year, Tyra Biosciences, Inc.’s market cap is up 45.23%, using historical market-cap records rather than today’s share count applied to past prices.
Tyra Biosciences, Inc. (TYRA) shares trade at $19.67, down 0.44% on the day, as of November 17, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.